Foresight Diagnostics

Foresight Diagnostics is a cancer diagnostics company developing a novel liquid biopsy test to detect relapse sooner. Foresight’s approach is a highly sensitive liquid biopsy minimal residual disease (MRD) test that is optimized to detect even the earliest hints of cancer relapse. The test uses Foresight’s patented PhasED-seq technology that leverages the sequencing of phased variants for ultrasensitive and highly specific detection of circulating tumor DNA (ctDNA). This enables detection of ctDNA at levels below one part-per-million. The MRD technology has been validated in thousands of patient samples with B-cell malignancies, lung cancer and breast cancer